A broad spectrum of adverse reactions associated with the use of tumor necrosis factor alpha (TNFα) antagonists has been recognized over the past years. Induction of scalp psoriasis is a less known undesirable consequence of the use of these drugs and is not well characterized.
Objective
To characterize TNFα inhibitors-induced psoriatic alopecia.
Methods
We studied 6 patients with TNF-inhibitor induced psoriatic alopecia and reviewed 28 patients with this condition reported in the literature to date.
Results
In addition to severe scalp psoriasis, we report hair follicle pathologies ranging from alopecia areata to scarring alopecia. Prognosis was good, but discontinuation of TNFα inhibitors was required in more than half of the cases in order to achieve a favourable outcome.
Conclusion
TNFα inhibitors-associated psoriatic alopecia is rarely reported but requires a high index of suspicion and prompt diagnosis, as timely intervention may prevent irreversible damage.
GarcovichSDe SimoneCGenoveseGBertiECugnoMMarzanoAV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.
2.
MoustouA-EMatekovitsADessiniotiCAntoniouCSfikakisPPStratigosAJ. Cutaneous side effects of anti – tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486-504.
3.
CollamerANGuerreroKTHenningJSBattafaranoDF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996-1001.
4.
WollinaUHanselGKochASchonlebeJKostlerEHaroskeG. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1-14.
5.
BrownGWangELeonA, et al.Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76(2):334-341.
6.
GarcovichSDe SimoneCGenoveseGBertiECugnoMMarzanoAV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.
7.
PapadavidEGaziSDalamagaMStavrianeasNNtelisV. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008;22(3):380-382.
8.
El Shabrawi-CaelenLLa PlacaMVincenziCHaidnTMuelleggerRTostiA. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis. 2010;16(2):182-183.
9.
DoyleLASperlingLCBakshS, et al.Psoriatic alopecia/alopecia areata–like reactions secondary to anti–tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011;33(2):161-166.
10.
OsórioFMagroFLisboaC, et al.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology. 2012;225(2):163-167.
11.
KawashimaKIshiharaSYamamotoA, et al.Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn’s disease. Inflamm Bowel Dis. 2013;19(3):E33-E34.
12.
AndrisaniGMarzoMCellenoL, et al.Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci. 2013;17(20):2831-2836.
13.
Toda-BritoHLopesLSoares-AlmeidaLFilipeP. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn’s disease. Dermatol Online J. 2015;21(11):13030/qt79j1d2jv.
14.
RibeiroLBRegoJCEstradaBDBastosPRPineiro MaceiraJMSodreCT. Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol. 2015;90(2):232-235.
15.
CraddockLNCooleyDMEndoJOLongleyBJCalderaF. TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold. Dermatol Online J. 2017;23(3):13030.
16.
Melé-NinotGExpósito-SerranoVQuintana CodinaM, et al.Adalimumab-related alopecia in a patient affected by psoriasis. Dermatol Online J. 2017;23(7):13030.
17.
UdkoffJCohenPR. Tumor necrosis factor-induced alopecia: alternative pathology and therapy. Dermatol Online J. 2017;23(6):13030.
ShimokataMNamikiTTokoroSUgajinTMiuraKYokozekiH. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab. J Dermatol. 2018;45(12):e331-e333.
20.
OzkurEAltunayIKLeblebiciCTopkarciZErdemY. Adalimumab-induced scalp psoriasis with severe alopecia. Dermatol Ther. 2019;32(5):e13033.
21.
KoumakiDKoumakiVKatoulisA, et al.Adalimumab-induced scalp psoriasis with severe alopecia as a paradoxical effect in a patient with Crohn's disease successfully treated with ustekinumab. Dermatol Ther. 2020;33(4):e13791.
22.
BonomoLde MollEHLiLGellerLGordonMIDunkinD. Tumor Necrosis factor inhibitor-induced Psoriasis in a pediatric Crohn's disease patient successfully treated with Ustekinumab. J Drugs Dermatol JDD. 2020;19(3):328-331.
23.
CarrasquilloOYPabon-CartagenaGBarrera-LlauradorJColon-FontanezFMartin-GarciaRF. Psoriatic alopecia in a patient with Crohn Disease: an uncommon manifestation of Tumor Necrosis factor α inhibitors. Cutis. 2021;107(4):E48-E55.
24.
JeongKMSeoJYKimABaekYSSongHJJeonJ. Tumor Necrosis Factor-alpha inhibitor-associated psoriatic alopecia in a patient with ulcerative colitis: a case report and review of the literature. Ann Dermatol. 2021;33(1):82-85.
25.
SeneschalJMilpiedBVergierBLepreuxSSchaeverbekeTTaïebA. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161(5):1081-1088.
HoffmannREichelerWHuthAWenzelEHappleR. Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res. 1996;288(3):153-156.
28.
PelivaniNHassanASBraathenLRHungerREYawalkarN. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology. 2008;216(4):320-323.
29.
OnoSMiyachiYArakawaA. Hair regrowth following TNF-alpha blockade in coexisting psoriasis vulgaris and alopecia areata. Eur J Dermatol. 2013;23(4):537.
30.
BuiKPolisettySGilchristHJacksonSMFredericJ. Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. Cutis. 2008;81(5):431-434.
StroberBESiuKAlexisAF, et al.Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52(6):1082-1084.
33.
PostenWSwanJ. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol. 2005;141(6):759-760.
34.
EttefaghLNedorostSMirmiraniP. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004;140(8):1012.
35.
Garcia BartelsNLeeH-HWormMBurmesterG-RSterryWBlume-PeytaviU. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol. 2006;142(12):1654-1655.
36.
DoyleLASperlingLCBakshS, et al.Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011;33(2):161-166.
37.
YanaiHAmir BarakHOllechJE, et al.Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic. Therap Adv Gastroenterol. 2021;14:17562848211053112.
38.
LiSJPerez-ChadaLMMerolaJF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70-80.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
